Venture capital investment in early-stage biotechnology and pharmaceutical startups is seeing exuberance that could be classed as “froth,” but it does not appear to be in bubble territory yet.
{iframe}https://medcitynews.com/2018/07/biopharma-1h18-series-a-investment-exceeds-funding-for-all-of-2017/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=64599231&_hsenc=p2ANqtz-8s3Cnh9z7_HgJlc0587WG0FK16uFgwlpyQGDZzX5pANUox6p6zuresfWiaqkkPBJ2i6R1Is7JQKCV9cw8LlgNZFKRn-g&_hsmi=64599231{/iframe}